Bliss GVS Pharma Publishes Audited Financial Results for FY26 Q4
Bliss GVS Pharma published audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. For Q4 FY26, standalone revenue was ₹8,695.83 crore and consolidated revenue was ₹9,297.41 crore. Full-year standalone revenue reached ₹35,299.31 crore, and consolidated revenue was ₹37,840.44 crore.
Publication of financial results is a material event for investors and stakeholders, impacting investment decisions.
The announcement is a routine publication of financial results and does not contain any particularly positive or negative news.
Bliss GVS Pharma Limited has announced the publication of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. This intimation is in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company has published extracts of these financial results in various English, Regional, and Marathi dailies on May 14, 2026. These include 'The Economic Times', 'The Free Press Journal', 'Maharashtra Times', and 'Navshakti'.
In addition to the newspaper publications, the complete financial results are accessible via a Quick Response Code (QR Code) and a weblink provided in the advertisements. The company's website, https://www.blissgvs.com/, will also host this information.
The published financial data for the quarter ended March 31, 2026, shows total revenue of ₹8,695.83 crore standalone and ₹9,297.41 crore consolidated. Profit after tax for the quarter was ₹209.93 crore standalone and ₹212.10 crore consolidated. For the full year ended March 31, 2026, total revenue stood at ₹35,299.31 crore standalone and ₹37,840.44 crore consolidated. Profit after tax for the full year was ₹774.15 crore standalone and ₹703.51 crore consolidated.
The announcement also includes details regarding the publication of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, in accordance with SEBI regulations. The company has provided links and QR codes for accessing the full financial results.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.